# A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

> **NCT00995007** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 112 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Gliosarcoma
- Anaplastic Astrocytoma
- Anaplastic Oligodendroglioma
- Anaplastic Mixed Oligoastrocytoma

## Interventions

- **DRUG:** ZD6474 (Vandetanib)
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00995007
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2015-06
- **Final completion:** 2015-12
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2016-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00995007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00995007, "A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00995007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*